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ABSTRACT Quiescent, full-grown Xenopus oocytes,
which are arrested at the G2/M border of meiosis, contain an
inactive 42-kDa mitogen-activated protein kinase (p42MAPK)
that is activated when oocytes are stimulated to resume the
meiotic cell cycle. We have made extracts from these oocytes
that respond to four cell cycle activators: oncogenic [Val'2]Ras
protein, clam cyclins AA60 and BA97, and the phosphatase
inhibitor okadaic acid. All four induce the tyrosine phosphor-
ylation and activation of p42MAPK. Both cyclins and okadaic
acid, but not [Val'2]Ras, also lead to activation of the endog-
enous cyclin B/cdc2 kinase complexes in extracts of quiescent
oocytes. Using extracts prepared from cycloheximide-arrested
interphase cells, we show that although p42MAPK activation can
occur in response to cyclin-activated cdc2, the Ras-induced
activation of p42MAPK occurs without intervening cdc2 activa-
tion. Neither the nononcogenic [Gly12]Ras nor [Val12,Arg'']-
Ras, a mutant that lacks the C-terminal consensus sequence
directing prenylation and subsequent membrane association, is
an effective activator of p42MAPK in vitro.
Ras proteins are low molecular weight, membrane-
associated, guanine nucleotide-binding proteins involved in
signal transduction events in a wide variety of organisms (1).
Mutant, activated Ras proteins, with impaired ability to
hydrolyze GTP, are commonly found in malignantly trans-
formed cells (2-7). Although Ras is required for the action of
many other oncogene products and growth factors (8, 9), the
function of Ras proteins in higher organisms is unclear.
Virtually all mitogens and many other extracellular signals
induce the rapid, transient activation of MAP kinases via
phosphorylation on tyrosine and threonine residues (re-
viewed in refs. 10 and 11). The requirement for Ras in growth
factor-induced activation of MAP kinases (8, 9, 12) and the
ability of mutant, activated Ras to induce MAP kinase
activation in cultured cells (8, 9, 13) suggest that Ras is a
converging point for numerous signal transduction pathways.
MAP kinase activation is perhaps the earliest known bio-
chemical marker for Ras function in vertebrates.
Unlike most vertebrate somatic cells, which are arrested in
Go, Xenopus oocytes are arrested in prophase at the G2/M
border of meiosis. Progesterone stimulation leads to the
activation of a preexisting 42-kDa MAP kinase (p42MAPK)
(14-16) and cyclin B/cdc2 complexes known as pre-MPF
(maturation-promoting factor; reviewed in ref. 17) and re-
sumption of the cell cycle (reviewed in refs. 18 and 19). Since
injection of oncogenic Ras (20, 21) or cyclins (22-24) into
oocytes can also lead to cell cycle reentry, oocytes offer a
useful system in which these pathways can be analyzed. Here
we show that injection of oncogenic Ras into G2/M-arrested
oocytes leads to the activation of p42MAPK. We have also
established a cell-free system from oocytes that maintains the
quiescent state in vitro while retaining the capacity to re-
spond to cell cycle activators. This cell-free system repro-
duces the Ras-dependent activation of p42MAPK, as well as
other events that can lead to cell cycle reentry, including the
cyclin-induced conversion of cyclin B/cdc2 pre-MPF com-
plexes to active MPF.
MATERIALS AND METHODS
Construction of Escherichia coli Expression Vectors. PCRs
(Taq polymerase, Perkin-Elmer) (25) were performed by
Vincent Jung to generate Ha-ras genes with the desired
mutations and BamHI as the cloning site (underlined). The 5'
oligonucleotide used was 5'-CCCTGAGGjATCCATGAC-
GAATATAAG-3' which created a BamHI site (underlined)
upstream of the initiation codon (in bold); the 3' oligonucle-
otide was 5'-CCTCAGGATCCTCAGGAGAGCACA-
CACTT-3'. The 3' oligonucleotide used to mutate the mem-
brane localization site was 5'-CCTCAGGATCCTCAG-
GAGAGCACACGCCTT-3' with a point mutation (in bold) to
change Cys'86 (CAC) to Arg (CGC). The PCR templates were
derived from [Gly12]Ha-ras (wild type) and [Vall2]Ha-ras
cDNAs (26). These PCR products were first cloned into
ADHI promoter-driven expression vectors for Saccharomy-
ces cerevisiae (27) to confirm their biological activity (28).
Expression of [Gly12]Ha-ras in yeast suppressed the temper-
ature sensitivity of a strain containing the temperature-
sensitive mutation ras2ts. Expression of [Val'2]Ha-ras con-
ferred heat shock sensitivity on a wild-type strain and sup-
pressed the lethality of a strain containing cdc25ts. Finally,
expression of [Val"2,Arg186]Ha-ras suppressed the heat shock
sensitivity of a strain containing [Val19]RAS2 (29). The frag-
ments were cloned into pTrcHis (Invitrogen, San Diego) and
expressed as fusion proteins with N-terminal oligohistidine
(30, 31).
Purification of Intact and Histidine-Tagged Fusion Proteins.
Ha-Ras proteins were purified as described (32). His-tagged
proteins were prepared according to ref. 31 and manufactur-
er's instructions (Invitrogen). The His6-Ras proteins were
solubilized in sonication buffer [10 mM Tris HCI, pH 7.5/10
mM MgCl2/50 mM NaCI/1 ,M phenylmethanesulfonyl flu-
oride/20 AM leupeptin/aprotinin (2 ,tg/ml)/2 AM pepstatin/
0.5% (wt/vol) dodecyl f3-D-maltoside (Boehringer Mann-
heim)]. The protein was bound to Pro-Bond resin (Invitrogen)
overnight at 4°C and eluted with increasing imidazole con-
centrations. Fractions containing His-tagged proteins, iden-
tified by immunoblotting, were dialyzed against microinjec-
tion buffer (20 mM Hepes, pH 7.4/20 mM NaCl/4 mM
MgCl2/0.5 mM 2-mercaptoethanol). His6-Ras preparations
(at least 70% pure) were concentrated using Centriprep-10
concentrators (Amicon) and stored at -70°C in microinjec-
Abbreviations: MAP kinase, mitogen-activated protein kinase;
p42MAPK, 42-kDa MAP kinase; MPF, maturation-promoting factor;
GVBD, germinal vesicle breakdown; MBP, myelin basic protein;
CHX, cycloheximide.
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tion buffer plus 40% glycerol. The purification of His6-ERK2
from E. coli carrying the NTP7-5 vector was performed using
identical conditions, but without dodecyl f3-D-maltoside.
Recombinant clam cyclins AA60 and BA97 were expressed
and gel-purified as described (33).
Frog Oocyte Maturation Assays. Oocyte isolation, micro-
injection, and culture were as described (33). Oocytes were
microinjected with 50 nl and germinal vesicle breakdown
(GVBD) was scored by the appearance of a white spot at the
animal pole. For immunoblot analysis, 4 vol of lysis buffer
(0.25 M sucrose/0.1 M NaCI/2.5 mM MgCl2/10 mM NaF/10
mM EGTA/1.0 mM Na3VO4/20 mM Hepes, pH 7.2) was
added to 1 vol of packed oocytes (0.9 1.l per oocyte), and
oocytes were homogenized by repeated passage through a
plastic pipette tip. The homogenate was centrifuged at 10,000
x g for 5 min and mixed with 4 vol of 2x sample buffer (34).
Preparation of Oocyte and Egg Extracts. Defolliculated, late
stage V and VI oocytes, .1.2 mm (35), were isolated from
ovaries by collagenase treatment (36, 37), rinsed twice in
extraction buffer (EB: 0.25 M sucrose/0.1 M NaCl/2.5 mM
MgCl2/20 mM Hepes, pH 7.2), and then transferred to a 5-ml
centrifuge tube containing EB with pepstatin, chymostatin,
and leupeptin (each at 10 ,g/ml). Excess EB was removed
and oocytes were crushed by centrifugation at 15,000 x g for
15 min in a swinging-bucket rotor at 2°C. The supernatant
between the lipid cap and packed yolk was collected and
cytochalasin B was added (50 ,ug/ml) before a second cen-
trifugation under the same conditions. Aliquots were frozen
in liquid nitrogen and stored at -80°C. Fresh and frozen/
thawed extracts responded equally well to added proteins.
Ovulated, metaphase II-arrested eggs were obtained and
dejellied (38). Extracts were prepared from unactivated eggs
as described for oocytes except that the EB contained 10mM
NaF (recrystallized, Sigma) and 10 mM EGTA (Sigma). To
prepare cycloheximide (CHX)-arrested extracts, dejellied
metaphase II-arrested eggs were incubated in 20% modified
Steinberg's solution (39) with CHX (100 ,ug/ml, Sigma) for 15
min, electrically activated (40), and then cultured in this
solution for 45 min at 21°C. Extracts were prepared as
described for oocytes.
In Vitro Assays of p42MAPK Activation. Assay samples
(25-60 ,ul) were prepared by mixing 16 vol of extract, 1 vol
of an ATP-regenerating system [20 mM ATP, 20 mM MgCl2,
0.2 M creatine phosphate, and creatine kinase (1 mg/ml,
Boehringer Mannheim) in EB], and 3 vol of EB or other
additions. For assay of Ras, 5.0-mg/ml preparations were
diluted with 1 vol of dilution buffer [50 mM NaCl/2 mM
MgCl2/20 mM Hepes, pH 7.4 (20)] and added to extracts at
a dilution of 1:19, to yield a final concentration of 125 Ag/ml.
Purified His6-Ras proteins were subjected to a GTP-exchange
reaction by mixing 1 vol of protein preparation (5.0 mg/ml)
with 1 vol of exchange buffer (50 mM NaCl/1 mM dithio-
threitol/10 mM EDTA/2 mM GTP/50 mM Tris HCl, pH 7.5)
and incubating at 37°C for 10 min, before addition to extracts.
In addition, all Ras assays included 1 mM GTP. For assay of
cyclins, samples included 3 vol of 40mM Tris acetate, pH 7.2
with either cyclin AA60 (0.15 mg/ml) or cyclin BA97 (0.25
mg/ml), to yield final concentrations in extracts of 0.5 AM
and 0.9 ,uM, respectively. Okadaic acid was added to a final
concentration of 1.0 ,uM in samples. For in vitro activation of
His6-ERK2, the protein was added to extracts to yield a final
concentration of 150 ,ug/ml. After mixing on ice, samples
were incubated at 21°C and aliquots were analyzed by
immunoblotting (1 vol of extract/10 vol of sample buffer) or
kinase assays (1 vol of extract/10 vol of lysis buffer). Meta-
phase II-arrested egg extract was diluted with EB and sam-
ples were prepared in the same manner.
Immunoblotting. Immunoblotting with MAP kinase anti-
sera (anti-ERKi 691 and 837; ref. 41), phosphotyrosine
antibodies (42), and affinity-purified cdc2 antibodies was as
described (33, 43), using alkaline phosphatase-conjugated
secondary antibody (Promega).
Isolation ofHis6-ERK2 and Endogenous cdc2 from Extracts,
and Kinase Assays. To recover His6-ERK2 from the extracts,
10 Ad of extract was mixed with 20 A.l of EB/10 mM NaF/1
mM Na3VO4/120 mM imidazole and then frozen in liquid
nitrogen. Pro-Bond resin was prepared as a 1:1 slurry in
EB/10mM NaF/1 mM Na3VO4 and 20 jul was added to each
thawed sample and mixed for 30 min at 40C. The pelleted
resin was then washed once in EB containing 0.5 M NaCl, 40
mM imidazole, 0.2% Tween 20,0.2 mM Na3VO4, and 10 mM
NaF; twice in the same buffer, but with 0.1 M NaCl; and
finally, once in this buffer without Tween 20. The resin was
suspended in 40 Al of final wash buffer, and 5 pl was assayed
for kinase activity with myelin basic protein (MBP) as
substrate. The remaining resin was pelleted and bound pro-
tein was eluted with 30 ,l of sample buffer for analysis by
immunoblotting. cdc2 kinase was isolated on p13sucl-
Sepharose (33), using the same buffers as those used for
His6-ERK2 isolation, but without imidazole. Histone H1
kinase or MBP kinase assays of samples were done as
described (43). H1 bands were excised from dried gels and
immersed in Aquasol (DuPont), and 32p incorporation was
quantitated in a scintillation counter. The in-the-gel kinase
assay was as described (16, 44).
RESULTS
Ras-Induced Oocyte Maturation Is Accompanied by Tyro-
sine Phosphorylation of p42MAPK. Injection of human onco-
genic [Val12]Ha-Ras into quiescent frog oocytes leads to
resumption of the meiotic cell cycle as judged by GVBD.
With the relatively low-specific-activity preparation used for
Fig. 1, only the highest amount of Ras (100 ng) induced
GVBD in a significant number of oocytes (40%; data not
shown). To monitor the status ofp42MAPK, lysates were made
from oocytes before or 5 hr after injection or progesterone
treatment and analyzed by immunoblotting. Quiescent
oocytes contained a 42-kDa protein that was recognized by
MAP kinase antibodies but not by phosphotyrosine antibod-
ies (Fig. 1). Both progesterone-matured and Ras-matured
oocytes showed almost complete conversion of the p42MAPK
to a more slowly migrating form that was recognized by
phosphotyrosine antibodies and represented, as previously
shown (14, 45, 46), the active form of the enzyme. Both also
showed the tyrosine dephosphorylation of a 34-kDa protein,
identified here (see below) and elsewhere (47-49), as cdc2
kinase. In this system and others, tyrosine dephosphoryla-
tion of cdc2 is a reliable marker of its activation (50-55). A
considerable fraction of p42MAPK was tyrosine-phosphory-
lated even in the Ras-injected oocytes, which did not undergo
GVBD. However, there was no significant tyrosine dephos-
phorylation ofcdc2 in these oocytes, suggesting that p42MAPK
activation neither depends on nor follows cdc2 activation.
Ras- and Cyclin-Induced Activation of p42MAPK in Extracts
of Quiescent Oocytes. To test if cell cycle activators could
induce p42MAPK activation in an extract of quiescent oocytes,
a 15,000 x g extract was prepared and supplemented with
GTP and an ATP-regenerating system. Both p42MAPK (Fig. 2
A and B) and cdc2 (Fig. 2C) remained inactive for up to 4 hr
of incubation at 21°C. The addition of [Val'2]Ras induced the
activation of p42MAPK 2-3 hr later, as judged by the shift in
its electrophoretic mobility, coincident with the appearance
of both a phosphotyrosine signal at 42 kDa (Fig. 2A) and a
42-kDa-associated kinase activity toward MBP (Fig. 2B).
Boiled Ras had no activity (data not shown). Although
His6-[Val12]Ras had activity comparable to untagged
[Val12]Ras, nononcogenic His6-[Glyl2]Ras was a much less
effective activator of p42MAPK in oocyte extracts (Fig. 2D).
His6-[Val12,Arg186]Ras, a mutant that cannot undergo pren-
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FIG. 1. Ras induces tyrosine phosphorylation of p42MAPK in
Xenopus oocytes. Immature oocytes, oocytes treated with proges-
terone, or oocytes incubated with or without CHX, then injected
with the indicated amount ofrecombinant human [Val12]Ras protein,
were collected 5 hr after injection. Untreated oocytes and oocytes
injected with 25 or 50 ng ofRas all failed to undergo GVBD. The 40%
of the oocytes injected with 100 ng of [Val'2]Ras that underwent
GVBD were analyzed separately from the 60%6 that did not. Samples
were analyzed by blotting with antibodies against phosphotyrosine
(a-p-tyr) (Left) or a mammalian MAP kinase (a-ERK) (Right).
Molecular size markers are indicated by dashes: 220, 200, 116, 94, 56,
40, and 31 kDa. Lanes: a, Uninjected oocytes; b and c, 25 and 50 ng
of [Val12]Ras; d, 50 ng of [Val12]Ras injected into CHX-treated
oocytes; e, 100 ng of [Vall2]Ras (no GVBD); f, 100 ng of [Vall2]Ras
(GVBD); g, progesterone (GVBD). p42M"K was also recognized by
a second ERK antibody, 837, directed against the C terminus of the
protein (data not shown) (13, 41).
ylation and membrane association, could not activate
p42MAPK in vitro.
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While [Val12JRas led to activation of p42MAPK, it induced
neither the tyrosine dephosphorylation nor the activation of
cdc2 (Fig. 2C). In contrast, 1 1LM okadaic acid induced rapid
activation of both p42MAPK and cdc2 in oocyte extracts (Fig.
2 A-C), just as in intact oocytes (56).
Both clam cyclins, AA60 and BA97, also led to activation
of p42mAPK in oocyte extracts (Fig. 3). As judged by the
appearance of a phosphotyrosine signal at 42 kDa, p42MAPK
activation was first detected 60 min after cyclin addition. In
contrast to the Ras-induced activation of p42MAPK, cyclin-
induced p42MAPK activation was preceded by activation of
cdc2 kinase (as measured by histone H1 kinase activity) and
dephosphorylation of the cdc2 subunit of pre-MPF (Fig. 3).
A recombinant MAP kinase tagged with oligohistidine
(His6-ERK2) was also an effective target for Ras-induced
activation. Like other recombinant MAP kinases (57-59),
His6-ERK2 showed a low level of endogenous phosphoryla-
tion. When added to the quiescent oocyte extract, it remained
inactive for at least 4 hr, during which time it was dephos-
phorylated (Fig. 4). The addition of [Val12]Ras to the extracts
led to moderate tyrosine phosphorylation and activation of
His6-ERK2. In oocyte extracts stimulated by okadaic acid,
His6-ERK2 was completely converted to the upper, activated
form. Most strikingly, extracts of metaphase II-arrested
ovulated eggs, which contain high levels of active, endoge-
nous p42MAPK and MAP kinase kinase (15, 16, 46, 60, 61),
showed a very rapid activation ofthe added His6-ERK2, with
>50%o of the protein being shifted to the upper, active form
even at 4°C (Fig. 4).
Ras- and Cyclin-Induced Activation of p42mPK in Extracts
of CHX-Arrested Interphase Cells. Purified MPF can lead to
activation of frog p42MAPK, both during oocyte maturation in
vivo and in extracts of fertilized eggs. In contrast, injection of
active p42MAPK into quiescent oocytes does not lead to cdc2
activation or meiotic maturation (14, 60, 61). From these
results, it has been suggested that p42mAPK activation both
follows and is dependent on cdc2 activation. To test this idea,
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20000 FIG. 2 Ras induces the activation of p42MAPK in extracts of quiescent oocytes.] f l. (A) A 15,000 x g extract of quiescent, immature frog oocytes was incubated with
10000 buffer, [Val'2]Ras, or okadaic acid (OA) at 21'C. Aliquots were removed at the
indicated times (hr) and analyzed, along with an extract of mature, metaphase
I~ Il-arrested frog eggs (MII), by blotting with antibodies against phosphotyrosine0 hr 4 hr +ras +QA (a-p-tyr) (Upper) or MAP kinase (a-ERK) (Lower). (B) Samples obtained as in A
+Buffer 4 hr
were assayed for a 42-kDa-associated kinase activity against MBP by an in-the-gel
assay. (C) p13Ducl-Sepharose-bound proteins were isolated from samples taken at 0 or 4 hr of the experiment shown in A and blotted with
antibodies against phosphotyrosine (a-p-tyr) (Top) or yeast cdc2 (a-cdc2) (Middle). Arrowhead (Middle) indicates the position of the
phosphotyrosine form of cdc2 shown in Top. The same samples were assayed for histone H1 kinase activity (Bottom). (D) Oocyte extracts
were incubated with buffer or with Ras proteins N-terminally tagged with oligohistidine, His6-[Val12]Ras, His6-[Gly12]Ras, or His6-[Val12,Arg186]Ras, and assayed by immunoblotting as in A.
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FIG. 3. Clam cyclins AA60 and BA97 induce activation of both
cdc2 and p42MAPK in oocyte extracts. Extracts were incubated with
cyclins and samples were analyzed by blotting as in Fig. 2A with
antibodies against phosphotyrosine (a-p-tyr) (Top) or MAP kinase
(a-ERK) (Middle). Samples were also assayed for histone H1 kinase
activity (Bottom).
we made extracts that contained inactive cdc2 (40, 55, 62). To
prepare these, metaphase II-arrested eggs were treated with
CHX and then electrically activated to trigger entry into
interphase of the first mitotic cell cycle. At 45 min postacti-
vation, when endogenous cyclins had been destroyed, cdc2
activity had disappeared, and new cyclin synthesis had been
blocked, eggs were collected and an extract was made. The
addition of His6-[Val12]Ras to CHX extracts led to the
activation of p42MAPK in the complete absence of cdc2
activation (Fig. 5). Okadaic acid also stimulated p42MAPK, but
with less than a 2-fold increase in H1 kinase activity (not
shown). In contrast, addition ofeither cyclin AA6O (Fig. 5) or
cyclin BA97 (data not shown) activated both cdc2 and
p42MAPK, with cdc2 activation preceding that of p42MAPK.
Thus, p42MAPK can be activated in extracts of oocytes and
mitotic interphase cells by two pathways, a Ras-dependent
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FIG. 4. In vitro activation of exogenous, recombinant MAP
kinase. Oocyte or metaphase II-arrested egg (MII) extracts were
incubated for 0 or 4 hr as follows: oocyte extract plus His6-ERK2;
oocyte extract alone; oocyte extract plus 1 ,uM okadaic acid (OA) and
His6-ERK2; MII extract plus His6-ERK2. His6-ERK2 was recovered
from the lysates by binding to Pro-Bond resin and blotted with
antibodies against phosphotyrosine (a-p-tyr) (Top) or MAP kinase
(a-ERK) (Middle) and assayed for MBP kinase activity (Bottom).
DISCUSSION
We have developed a cell-free system from Xenopus oocytes
which reproduces the Ras-induced activation ofp42MAPK that
occurs when intact oocytes and other quiescent cells are
stimulated to reenter the cell cycle. The lag between Ras
addition and p42MAPK activation may reflect the need for the
processing ofRas, which is slow even in vivo (20). Ras proteins
normally undergo a complex set of modifications, resulting in
the cleavage, isoprenylation, methylation, and palmitoylation
of the C terminus of the protein concomitant with its mem-
brane localization (63). Whether or not this processing is
responsible for the delay in p42MAPK activation in vitro,
processing is most likely required, since [Vall2,Arg'86]Ras, a
mutant that lacks the C-terminal Cys-Ali-Ali-Xaa (Ali, ali-
phatic residue) motif (64), neither undergoes processing nor
induces p42MAPK activation. Although p42mAPK is activated by
Ras both in vivo and in vitro, we have not observed any
Ras-induced cdc2 activation in vitro. These results show that
the activation of oocyte p42MAPK by Ras does not occur via
cdc2 activation. Either oocyte extracts lack the capacity for
Ras-induced cdc2 activation or, alternatively, activation of
cdc2 by Ras in vitro may be much slower than that ofp42MAPK
and, therefore, not observed during the limited time monitored
in these studies.
The oocyte cell-free system also reproduces two other
events that can lead to cell cycle reentry in vivo, activation
of cdc2 by cyclins (22) and the phosphatase inhibitor okadaic
acid (56). Oocytes contain cdc2, some of which is complexed
with cyclin B and kept inactive by phosphorylation ofcdc2 on
tyrosine (reviewed in ref. 18). Hormonal stimulation induces
dephosphorylation and subsequent activation of cdc2 by a
homolog of the fission yeast phosphatase cdc25. Although
cdc2 dephosphorylation is thought to proceed via an auto-
catalytic amplification loop involving cdc25 (reviewed in refs.
65 and 66), it is not clear what triggers this loop during
normal, hormone-induced maturation. Our observation that
cyclins induce the tyrosine dephosphorylation ofendogenous
cdc2 in oocyte extracts suggests that added cyclins bind free
cdc2, forming active complexes that trigger activation of
cdc25, which, in turn, dephosphorylates and activates the
endogenous cdc2/cyclin B complexes.
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FIG. 5. Both cyclin and [Val12]Ras induce activation ofp42MAPK
in extracts of CHX-arrested interphase cells. Extracts of CHX-
arrested activated eggs were incubated with buffer, cyclin AA, or
His6-[Val12]Ras, and aliquots were removed at the indicated times
(hr). Samples were analyzed as in Fig. 3. (Top) Anti-phosphotyrosine
blot. (Middle) Anti-ERK blot. (Bottom) Histone H1 kinase activity.
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The normal pathway for p42MAPK activation in vivo is not
clear. A pathway for p42MAPK activation can be triggered, at
least experimentally, by introduction of MPF into intact
oocytes and fertilized egg extracts (14, 60, 61) or, as shown
here, by the addition of purified cyclins to oocyte and
embryonic extracts, yet the Ras-induced activation of
p42MAPK in these extracts occurs without any detectable
activation of cdc2. Similarly, in Go-arrested somatic cells,
Ras-induced activation of p42MAPK proceeds without any
apparent involvement of cdc2, since such cells lack signifi-
cant cdc2 protein or activity (67).
The establishment ofa cell-free assay from vertebrate cells
for Ras-induced p42MAPK activation should facilitate the
dissection of this pathway. Oocyte and egg extracts can be
prepared in large quantities, which may allow the biochem-
ical isolation of components of this pathway and the discov-
ery of their functions. In addition, specific hypotheses about
the roles of other proteins involved in the modulation of Ras
can now be tested directly.
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